Regeneron Pharmaceuticals Inc.’s (REGN) Arcalyst as a proposed treatment for gout was unanimously rejected by a federal advisory panel on Tuesday. The panel voted unanimously 11-0 stating Regeneron’s clinical trials were too short to prove the treatment was safe, or that it would help patients over time. The treatment is meant to be taken for 16 [...]
Regeneron’s Arcalyst As Gout Treatment Rejected By FDA Panel is a post from: The Inquisitr